EICHORPublic-registry site landscape for NCT05856331, “Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema”, a Alpha 1-Antitrypsin Deficiency study sponsored by Sanofi. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05856331 (registry record) |
| Study title | Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema |
| Official title | Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of SAR447537 (INBRX-101) Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema |
| Sponsor | Sanofi |
| Condition(s) | Alpha 1-Antitrypsin Deficiency; Emphysema |
| Phase | PHASE2 |
| Listed sites | 65 |
| Site countries | United States, Australia, Denmark, New Zealand, Poland, Spain, Sweden, United Kingdom |
Patient-friendly overview of this study: eichor.com/study/NCT05856331.
Eichor generates a preliminary site-risk snapshot for NCT05856331 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
